Journal article
Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
Abstract
BACKGROUND: Management of congenital hemophilia A and B is by prophylactic or on-demand replacement therapy with clotting factor concentrates. The effects of newer non-clotting factor therapies such as emicizumab, concizumab, marstacimab, and fitusiran compared with existing standards of care are yet to be systematically reviewed.
OBJECTIVES: To assess the effects (clinical, economic, patient-reported, and adverse outcomes) of non-clotting …
Authors
Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
Journal
Cochrane Database of Systematic Reviews, Vol. 2024, No. 2,
Publisher
Wiley
DOI
10.1002/14651858.cd014544.pub2
ISSN
1361-6137